Back to Search
Start Over
Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS
- Source :
- Intensive Care Medicine, Intensive Care Medicine, Springer Verlag, 2020, 46 (12), pp.2284-2296. ⟨10.1007/s00134-020-06289-8⟩
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- Current literature addressing the pharmacological principles guiding glucocorticoid (GC) administration in ARDS is scant. This paucity of information may have led to the heterogeneity of treatment protocols and misinterpretation of available findings. GCs are agonist compounds that bind to the GC receptor (GR) producing a pharmacological response. Clinical efficacy depends on the magnitude and duration of exposure to GR. We updated the meta-analysis of randomized trials investigating GC treatment in ARDS, focusing on treatment protocols and response. We synthesized the current literature on the role of the GR in GC therapy including genomic and non-genomic effects, and integrated current clinical pharmacology knowledge of various GCs, including hydrocortisone, methylprednisolone and dexamethasone. This review addresses the role dosage, timing of initiation, mode of administration, duration, and tapering play in achieving optimal response to GC therapy in ARDS. Based on RCTs’ findings, GC plasma concentration–time profiles, and pharmacodynamic studies, optimal results are most likely achievable with early intervention, an initial bolus dose to achieve close to maximal GRα saturation, followed by a continuous infusion to maintain high levels of response throughout the treatment period. In addition, patients receiving similar GC doses may experience substantial between-patient variability in plasma concentrations affecting clinical response. GC should be dose-adjusted and administered for a duration targeting clinical and laboratory improvement, followed by dose-tapering to achieve gradual recovery of the suppressed hypothalamic–pituitary–adrenal (HPA) axis. These findings have practical clinical relevance. Future RCTs should consider these pharmacological principles in the study design and interpretation of findings. Electronic supplementary material The online version of this article (10.1007/s00134-020-06289-8) contains supplementary material, which is available to authorized users.
- Subjects :
- ARDS
Hypothalamo-Hypophyseal System
[SDV]Life Sciences [q-bio]
Pituitary-Adrenal System
Review
Glucocorticoid receptor
Pharmacology
Critical Care and Intensive Care Medicine
Methylprednisolone
law.invention
03 medical and health sciences
0302 clinical medicine
Glucocorticoid
Randomized controlled trial
law
medicine
Receptor affinity
Humans
Glucocorticoids
Dexamethasone
Respiratory Distress Syndrome
Clinical pharmacology
Pharmacodynamic
Acute respiratory distress syndrome
Randomized trial
Duration
business.industry
030208 emergency & critical care medicine
medicine.disease
3. Good health
030228 respiratory system
Pharmacodynamics
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 03424642 and 14321238
- Database :
- OpenAIRE
- Journal :
- Intensive Care Medicine, Intensive Care Medicine, Springer Verlag, 2020, 46 (12), pp.2284-2296. ⟨10.1007/s00134-020-06289-8⟩
- Accession number :
- edsair.doi.dedup.....df00736ac30b88ba764ea46abc2bc40a
- Full Text :
- https://doi.org/10.1007/s00134-020-06289-8⟩